The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable excitement within the sector. A shift away from Schedule I status, often considered as outdated and hindering progress, could unlock significant possibilities for companies. Reduced regulatory burdens, alongside greater access to banking and in